Home › Chronic Lymphocytic Leukemia › NCT07030400
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included. * Subjects must be able to read and speak English or Spanish at the 8th grade level. Exclusion Criteria: * Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
About the study
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
What is being tested
- Bruton's tyrosine kinase inhibitor (drug)
- B-Cell Lymphoma 2 Protein Inhibitor (drug)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Participants: 100 · Started: Jul 17, 2025
Contact the study team
- Daniel Lastorino · Phone: 813-745-0092
Official record on ClinicalTrials.gov — NCT07030400
Locations in the U.S.
| Florida | Moffitt Cancer Center, Tampa |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.